The combination of human glandular kallikrein and free prostate-specific antigen (PSA) enhances discrimination between prostate cancer and benign prostatic hyperplasia in patients with moderately increased total PSA - Magklara, A; Scorilas, A; Catalona, WJ; Diamandis, EP (Clin Chem, 1999)